Relationship between cytokines and leukocytosis in patients with APL induced by all-trans retinoic acid or arsenic trioxide.
Leukocytosis or hyperleukocytosis occurs during ATRA or arsenic trioxide differentiation therapy, which is related to the RA syndrome. The number of WBC often increased by ten or more times as high as that of pretreatment, around 7 to 20 days after treatment with ATRA or arsenic trioxide. Usually, when number of WBC tended to peak, there was concomitance with down-regulation of promyelocytes, up-regulation of myelocytes and more mature neutrophils. The same trend of classification of BM was observed in most of the patients with APL to whom leukocytosis happened. Although the mechanism of leukocytosis has not been demonstrated clearly, so far the proliferation hypothesis by cytokines and rheological hypothesis by adhesion molecules were taken into consideration. Otherwise, hypothesis about more divisions of differentiated myelocytes induced by ATRA or arsenic trioxide remains unclear. Usually, this kind of leukocytosis or hyperleukocytosis itself requires no additional cytotoxic treatment.
Bi
Ke Hong
KH
Department of Hemotology, Shandong Qian-Fe-Shan Hospital, Jingshi Road 85, Jinan 250014, Shandong, China.
Jiang
Guo Sheng
GS
D000970:Antineoplastic Agents / Q000494:pharmacology*; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000494:pharmacology*; D016207:Cytokines / Q000378:metabolism / Q000502:physiology*; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy* / Q000378:metabolism*; D007964:Leukocytosis / Q000139:chemically induced* / Q000378:metabolism; D010087:Oxides / Q000494:pharmacology*; D014212:Tretinoin / Q000502:physiology*
D000970:Antineoplastic Agents; D001152:Arsenicals; D016207:Cytokines; D010087:Oxides; D014212:Tretinoin; D000077237:Arsenic Trioxide